Drug intelligence / Profile preview

APVO442

Development stage: Preclinical
Lead developer: Aptevo Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

APVO442 is a preclinical, investigational bispecific antibody developed by Aptevo Therapeutics. Engineered using the ADAPTIR-FLEX platform, it is designed to treat prostate cancer by targeting Prostate-Specific Membrane Antigen (PSMA) on cancer cells and CD3 on T cells. This dual targeting aims to selectively activate T cells within the tumor microenvironment, leading to targeted immune responses and enhanced tumor cell killing, while minimizing systemic toxicity and cytokine release through its optimized binding affinities.

Targets

PSMA (Prostate-specific membrane antigen)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on APVO442.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APVO442.

Explore the full profile